SKP Securities: Outcome of board meeting

hexa1

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSELIVE NSELIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher's research report on Divi's Laboratories

We reduce our FY24/FY25E EPS estimates by 7/6%. Divi’s Laboratories (DIVI) Q2FY24 EBITDA was 14% below our estimate led by lower margins. GMs declined on the back of pricing pressure, rise in input costs and inventory write off. Mgmt. suggested that moderation of raw material prices with commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. However, recovery will be gradual and near-term growth is likely to remain muted. We expect 16% EBITDA CAGR and 14% PAT CAGR over FY23-26E. At CMP, stock is trading at expensive valuations of 44x FY25E EPS.

Outlook

Maintain ‘Reduce’ rating with revised TP of Rs3,150/share (Rs3,000 earlier), valuing at 35x Sept 2025E P/E as we roll forward. Any sharp recovery in margin is key risk to our call.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More

Divi's Laboratories - 05 - 10-2023 - prabhu